RT Journal Article
SR Electronic
T1 Free fatty acids accelerate β-cell death in type 1 diabetes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.16.24313433
DO 10.1101/2024.09.16.24313433
A1 Elliott, Emily C.
A1 Sakar, Soumyadeep
A1 Bramer, Lisa
A1 Burnet, Meagan
A1 Kim, Young-Mo
A1 Yi, Xiaoyan
A1 Estevao, Igor L.
A1 Rewers, Marian
A1 Cambronne, Xiaolu A.
A1 Vehik, Kendra
A1 Arrojo e Drigo, Rafael
A1 Metz, Thomas O.
A1 Eizirik, Decio L.
A1 Webb-Robertson, Bobbie-Jo M.
A1 Mirmira, Raghavendra G.
A1 Nakayasu, Ernesto S.
YR 2024
UL http://medrxiv.org/content/early/2024/09/16/2024.09.16.24313433.abstract
AB Type 1 diabetes (T1D) results from autoimmune destruction of the insulin producing pancreatic β cells. The body’s lipid metabolism is strongly regulated during this process but there is a need to understand how this regulation contributes to the β-cell death. Here, we show that fatty acids are released from plasma lipoproteins in children during islet autoimmunity, prior to T1D onset. These fatty acids (FFAs) enhanced cytokine-mediated apoptosis in cultured insulin-producing cells by downregulating the production of nicotinamide adenosine dinucleotide (NAD) via its salvage pathway, as well as deregulated central carbon metabolism and impaired levels of ATP. Downregulation of the NAD salvage pathway and central carbon metabolism enzymes were further observed during T1D development, supporting that the pathways for NAD and energy production are compromised in vivo. Our findings show that fatty acids are released during islet autoimmunity, accelerating disease development through impaired NAD metabolism.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Catalyst Award from the Human Islet Research Network (HIRN) (to E.S.N) (via U24 DK104162) and by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants R01 DK138335 (to E.S.N., M.R., B.J.M.W.R and T.O.M.), U01 DK127505 (to E.S.N.), U01 DK127786 (to R.G.M, D.L.E, B.J.M.W.R and T.O.M.), R01 DK060581 (to R.G.M.), R01 DK105588 (to R.G.M.) The TEDDY Study is funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4 DK112243, UC4 DK117483, U01 DK124166, U01 DK128847, and Contract No. HHSN267200700014C from the NIDDK, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF. This work is supported in part by the NIH/NCATS Clinical and Translational Science Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR002535).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Pacific Northwest National Laboratory institutional review board deemed the project to not be human subject research and waived full ethical review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes